[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT05573048":3,"trial-entities:NCT05573048":77,"trial-summary:NCT05573048":81},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":22,"primary_purpose":23,"phases":24,"enrollment_info":26,"interventions":29,"primary_outcomes":36,"secondary_outcomes":41,"sex":42,"minimum_age":43,"maximum_age":17,"healthy_volunteers":15,"eligibility_criteria":44,"std_ages":54,"locations":57,"central_contacts":67,"overall_officials":68,"references":72,"see_also_links":73},"NCT05573048","22-003369","A Study of Optical Fusion Trans-Perineal Grid","Optical Fusion Trans-Perineal Grid","ENROLLING_BY_INVITATION","2026-12","2026-01","2026-01-14","2022-10-04","Mayo Clinic","OTHER",false,"The purpose of this research is to evaluate a new needle guide grid utilizing Clear Guide SCENERGY - MR with a grid embedded with VisiMARKER II to autoregister and target the prostate aiding in needle placement positioning. The proceduralist can utilize this technology to find the best needle path to target within the pelvis.",null,[19],"Prostate Biopsy",[21],"Prostate Ablation Procedure","INTERVENTIONAL","DEVICE_FEASIBILITY",[25],"NA",{"count":27,"type":28},20,"ESTIMATED",[30],{"type":31,"name":32,"description":33,"armGroupLabels":34},"DEVICE","Trans-Perineal Grid","A small square piece of plastic with many holes in it placed between the legs to help guide the path of the interventional instruments and to facilitate the prostate intervention. The guide grid will help with needle placement using the grid technology.",[35],"Trans-Perineal Grid for prostate interventions",[37],{"measure":38,"description":39,"timeFrame":40},"Needle placement accuracy","Number of needle placements to successfully match target and needle tip position assessed by direct MR imaging and","Baseline",[],"MALE","45 Years",{"inclusion":45,"exclusion":50,"raw_text":53},[46,47,48,49],"Scheduled for a MR guided biopsy or ablation.","One, two, or three tumor suspicious regions identified on multiparametric MRI.","Tolerance for anesthesia\u002Fsedation.","Ability to give informed consent.",[51,52],"Presence of any condition (e.g., metal implant, shrapnel) not compatible with MRI.","History of other primary non-skin malignancy within previous three years.","Inclusion Criteria:\n\n* Scheduled for a MR guided biopsy or ablation.\n* One, two, or three tumor suspicious regions identified on multiparametric MRI.\n* Tolerance for anesthesia\u002Fsedation.\n* Ability to give informed consent.\n\nExclusion Criteria:\n\n* Presence of any condition (e.g., metal implant, shrapnel) not compatible with MRI.\n* History of other primary non-skin malignancy within previous three years.",[55,56],"ADULT","OLDER_ADULT",[58],{"facility":59,"city":60,"state":61,"zip":62,"country":63,"geoPoint":64},"Mayo Clinic Minnesota","Rochester","Minnesota","55905","United States",{"lat":65,"lon":66},44.02163,-92.4699,[],[69],{"name":70,"affiliation":13,"role":71},"David Woodrum, MD, PhD","PRINCIPAL_INVESTIGATOR",[],[74],{"label":75,"url":76},"Mayo Clinic Clinical Trials","https:\u002F\u002Fwww.mayo.edu\u002Fresearch\u002Fclinical-trials",{"nct_id":4,"conditions":78,"biomarkers":80},[79],"Prostate Carcinoma",[],{"nct_id":4,"found":15,"summary":17,"prompt_version":17}]